Mealey's (February 5, 2016, 12:23 PM EST) -- NEW YORK — A federal judge in New York on Feb. 2 granted preliminary approval of a $3 million settlement between shareholders and a pharmaceutical company and certain of its current and former officers and directors who are alleged to have misrepresented several stock transactions and “improper practices” in violation of federal securities law (In re Retrophin Inc. Securities Litigation, No. 14-8376, S.D. N.Y.)....